Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study.
BACKGROUND
A growing body of observational evidence supports the value of ceftazidime-avibactam (CAZ-AVI) in managing infections caused by carbapenem-resistant Enterobacteriaceae.


METHODS
We retrospectively analyzed observational data on use and outcomes of CAZ-AVI therapy for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp) strains. Multivariate regression analysis was used to identify variables independently associated with 30-day mortality. Results were adjusted for propensity score for receipt of CAZ-AVI combination regimens versus CAZ-AVI monotherapy.


RESULTS
The cohort comprised 577 adults with bloodstream infections (n = 391) or nonbacteremic infections involving mainly the urinary tract, lower respiratory tract, and intra-abdominal structures. All received treatment with CAZ-AVI alone (n = 165) or with ≥1 other active antimicrobials (n = 412). The all-cause mortality rate 30 days after infection onset was 25% (146/577). There was no significant difference in mortality between patients managed with CAZ-AVI alone and those treated with combination regimens (26.1% vs 25.0%, P = .79). In multivariate analysis, mortality was positively associated with presence at infection onset of septic shock (P = .002), neutropenia (P < .001), or an INCREMENT score ≥8 (P = .01); with lower respiratory tract infection (LRTI) (P = .04); and with CAZ-AVI dose adjustment for renal function (P = .01). Mortality was negatively associated with CAZ-AVI administration by prolonged infusion (P = .006). All associations remained significant after propensity score adjustment.


CONCLUSIONS
CAZ-AVI is an important option for treating serious KPC-Kp infections, even when used alone. Further study is needed to explore the drug's seemingly more limited efficacy in LRTIs and potential survival benefits of prolonging CAZ-AVI infusions to ≥3 hours.
['Tumbarello|Mario|M|', 'Raffaelli|Francesca|F|', 'Giannella|Maddalena|M|', 'Mantengoli|Elisabetta|E|', 'Mularoni|Alessandra|A|', 'Venditti|Mario|M|', 'De Rosa|Francesco Giuseppe|FG|', 'Sarmati|Loredana|L|', 'Bassetti|Matteo|M|', 'Brindicci|Gaetano|G|', 'Rossi|Marianna|M|', 'Luzzati|Roberto|R|', 'Grossi|Paolo Antonio|PA|', 'Corona|Alberto|A|', 'Capone|Alessandro|A|', 'Falcone|Marco|M|', 'Mussini|Cristina|C|', 'Trecarichi|Enrico Maria|EM|', 'Cascio|Antonio|A|', 'Guffanti|Elena|E|', 'Russo|Alessandro|A|', 'De Pascale|Gennaro|G|', 'Tascini|Carlo|C|', 'Gentile|Ivan|I|', 'Losito|Angela Raffaella|AR|', 'Bussini|Linda|L|', 'Corti|Giampaolo|G|', 'Ceccarelli|Giancarlo|G|', 'Corcione|Silvia|S|', 'Compagno|Mirko|M|', 'Giacobbe|Daniele Roberto|DR|', 'Saracino|Annalisa|A|', 'Fantoni|Massimo|M|', 'Antinori|Spinello|S|', 'Peghin|Maddalena|M|', 'Bonfanti|Paolo|P|', 'Oliva|Alessandra|A|', 'De Gasperi|Andrea|A|', 'Tiseo|Giusy|G|', 'Rovelli|Cristina|C|', 'Meschiari|Marianna|M|', 'Shbaklo|Nour|N|', 'Spanu|Teresa|T|', 'Cauda|Roberto|R|', 'Viale|Pierluigi|P|']
D000328:Adult D000900:Anti-Bacterial Agents D053961:Azabicyclo Compounds D001426:Bacterial Proteins D002442:Ceftazidime D004338:Drug Combinations D006801:Humans D007710:Klebsiella Infections D007711:Klebsiella pneumoniae D008826:Microbial Sensitivity Tests D012189:Retrospective Studies D001618:beta-Lactamases
ceftazidime-avibactam KPC-producing Klebsiella pneumoniae carbapenemases